Canada-EU trade deal will increase drug costs for Canadians

Brand-name pharmaceuticals could lead to skyrocketing health care bills

A new trade deal between Canada and the EU could add about $2.8-billion in annual costs to Canadian drug plans, according to a report commissioned by the Canadian Generic Pharmaceutical Association. The EU has asked for significant changes to patent laws for generic drugs, which regulate the amount of time before a generic drug company can reproduce a patented brand name drug. Patented drugs are generally more expensive than their generic counterparts. The changes include extending patent protection by up to 5 years, lengthening data exclusivity, and strengthening notice of compliance regulations. Aiden Hollis, professor of economics at the University of Calgary and the co-author of the report, said “the reasonable inference is that these changes are designed to allow innovating pharmaceutical firms to charge monopoly prices for a longer period.” Brand name drugs manufactured in the EU are a leading export to Canada, with $5.3-billion in pharmaceutical products imported by Canada from the EU in 2009.

The Globe and Mail

Looking for more?

Get the Best of Maclean's sent straight to your inbox. Sign up for news, commentary and analysis.